SomaLogic, Inc. (SLGC): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLGC Stock Price Chart Interactive Chart >
SLGC Price/Volume Stats
| Current price | $9.31 | 52-week high | $14.72 |
| Prev. close | $9.32 | 52-week low | $8.83 |
| Day low | $8.83 | Volume | 565,100 |
| Day high | $9.42 | Avg. volume | 1,001,760 |
| 50-day MA | $11.69 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.69B |
SomaLogic, Inc. (SLGC) Company Bio
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Latest SLGC News From Around the Web
Below are the latest news stories about SomaLogic Inc that investors may wish to consider to help them evaluate SLGC as an investment opportunity.
SomaLogic (SLGC) Presents At 40th Annual J.P. Morgan Healthcare Conference - SlideshowThe following slide deck was published by SomaLogic, Inc. in conjunction with this event.... |
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance RangePresenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern TimeBOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st, 2021. Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of SomaLogic’s previously raised 2021 revenue guidance range |
SomaLogic Announces Appointment of Adam Taich as Chief Business OfficerBOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer. In this newly created role, Adam will have broad responsibility across SomaLogic’s rapidly growing business to drive the company’s strategic and business development goals. He will also serve as a member of SomaLogic’s Executive Committee. Adam will report to SomaLogic Chief Executive Offic |
SomaLogic Announces Analyst and Investor Meeting on February 4, 2022BOULDER, Colo., Jan. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Friday, February 4, 2022, beginning at 10:00 a.m. Eastern Time. The virtual event will feature presentations from company leaders outlining SomaLogic’s unique positioning in proteomics, financial profile, and plans for continued business evolution and growth as the company furthers its scientific and commercial progress. The even |
SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutionsCo-developed and co-branded products to combine market-leading proteomic and genomic analysis platformsBOULDER, Colo., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration with Illumina, a global next-generation sequencing technology leader. The multi-year partnership agreement will bring together genomics and proteomics technology platforms in a major commercial partnership to better enable |
SLGC Price Returns
| 1-mo | -14.43% |
| 3-mo | -19.67% |
| 6-mo | -19.18% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -20.02% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...